11/26
06:00 am
onc
U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Low
Report
U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
11/24
09:04 am
onc
BeOne Medicines (NASDAQ:ONC) was given a new $400.00 price target on by analysts at Truist Financial Corporation.
Medium
Report
BeOne Medicines (NASDAQ:ONC) was given a new $400.00 price target on by analysts at Truist Financial Corporation.
11/24
08:43 am
onc
BeOne Medicines (NASDAQ:ONC) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Medium
Report
BeOne Medicines (NASDAQ:ONC) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
11/20
06:00 am
onc
BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025
Medium
Report
BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025
11/18
11:04 am
onc
BeOne Medicines (NASDAQ:ONC) had its price target raised by analysts at Royal Bank Of Canada from $395.00 to $408.00. They now have an "outperform" rating on the stock.
Low
Report
BeOne Medicines (NASDAQ:ONC) had its price target raised by analysts at Royal Bank Of Canada from $395.00 to $408.00. They now have an "outperform" rating on the stock.
11/17
04:11 pm
onc
BeOne Medicines (NASDAQ:ONC) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Medium
Report
BeOne Medicines (NASDAQ:ONC) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
11/17
06:00 am
onc
Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
Low
Report
Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
11/10
04:52 pm
onc
BeOne Medicines (NASDAQ:ONC) had its price target raised by analysts at Citigroup Inc. from $399.00 to $405.00. They now have a "buy" rating on the stock.
Medium
Report
BeOne Medicines (NASDAQ:ONC) had its price target raised by analysts at Citigroup Inc. from $399.00 to $405.00. They now have a "buy" rating on the stock.
11/7
01:43 pm
onc
BeOne Medicines (NASDAQ:ONC) had its price target raised by analysts at Royal Bank Of Canada from $374.00 to $395.00. They now have an "outperform" rating on the stock.
Low
Report
BeOne Medicines (NASDAQ:ONC) had its price target raised by analysts at Royal Bank Of Canada from $374.00 to $395.00. They now have an "outperform" rating on the stock.
11/7
09:06 am
onc
BeOne Medicines (NASDAQ:ONC) had its price target raised by analysts at Citizens Jmp from $348.00 to $396.00. They now have a "market outperform" rating on the stock.
Medium
Report
BeOne Medicines (NASDAQ:ONC) had its price target raised by analysts at Citizens Jmp from $348.00 to $396.00. They now have a "market outperform" rating on the stock.
11/6
06:00 am
onc
BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates
Medium
Report
BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates
10/30
10:48 am
onc
BeOne Medicines (NASDAQ:ONC) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
BeOne Medicines (NASDAQ:ONC) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
10/28
06:01 am
onc
BeOne Medicines to Present at Upcoming Investor Conferences
Low
Report
BeOne Medicines to Present at Upcoming Investor Conferences
10/22
06:01 am
onc
BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6
Low
Report
BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6
10/21
08:05 am
onc
The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners
Low
Report
The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners
10/20
11:15 am
onc
BeOne Medicines (NASDAQ:ONC) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Low
Report
BeOne Medicines (NASDAQ:ONC) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
10/20
06:00 am
onc
BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025
Low
Report
BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025
10/13
06:11 am
onc
BeOne Medicines' Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA [Yahoo! Finance]
Low
Report
BeOne Medicines' Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA [Yahoo! Finance]
10/13
06:00 am
onc
BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA
Low
Report
BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA
10/8
01:35 pm
onc
BeOne Medicines (NASDAQ:ONC) had its price target raised by analysts at JPMorgan Chase & Co. from $345.00 to $385.00. They now have an "overweight" rating on the stock.
Low
Report
BeOne Medicines (NASDAQ:ONC) had its price target raised by analysts at JPMorgan Chase & Co. from $345.00 to $385.00. They now have an "overweight" rating on the stock.
10/8
12:15 pm
onc
BeOne Medicines (NASDAQ:ONC) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
BeOne Medicines (NASDAQ:ONC) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/4
12:06 am
onc
Low
Report
10/2
01:55 am
onc
BeOne Medicines (ONC) Gains Barclays Overweight Rating Ahead of Key 2025 Data Readouts [Yahoo! Finance]
Low
Report
BeOne Medicines (ONC) Gains Barclays Overweight Rating Ahead of Key 2025 Data Readouts [Yahoo! Finance]
9/20
09:52 am
onc
BeOne Medicines (NASDAQ:ONC) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Low
Report
BeOne Medicines (NASDAQ:ONC) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
9/18
08:09 am
onc
BeOne Medicines (NASDAQ:ONC) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $385.00 price target on the stock.
Low
Report
BeOne Medicines (NASDAQ:ONC) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $385.00 price target on the stock.